By Noëlle Mennella PARIS (Reuters) – Sanofi wants any blame for the harmful effects of its epilepsy treatment Depakine on unborn babies to be shared with health authorities, doctors and pharmacists, according to the French drug company's scientific affairs director. The company has so far made no financial provisions for compensating victims and families affected by stillbirth, malformations and slow neurological development, believing that it has always fulfilled its obligations with regard to transparency, Pascal Michon told Reuters in an interview. Depakine is a branded form of the medication known as valproate which treats epilepsy and bipolar disorder.
Here is the original post:
Sanofi says blame over epilepsy drug should be shared
